Compare

Context Therapeutics Inc. vs Spero Therapeutics, Inc. vs Werewolf Therapeutics, Inc. vs Grace Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Context Therapeutics Inc. CNTX	Spero Therapeutics, Inc. SPRO	Werewolf Therapeutics, Inc. HOWL	Grace Therapeutics, Inc. GRCE
Year ended	2025-12-31	2025-12-31	2025-12-31	2026-03-31
Revenue	n/a	$66.80M	n/a	n/a
Revenue growth (YoY)	n/a	+39.2%	n/a	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	9.5%	n/a	n/a
Net margin	n/a	12.8%	n/a	n/a
Net income	-$36.12M	$8.57M	-$60.82M	-$7.79M
EPS (Diluted)	-$0.38	$0.15	-$1.33	-$0.47
Operating cash flow	-$26.39M	-$12.62M	-$60.29M	-$8.87M
Free cash flow	-$26.42M	n/a	-$60.29M	n/a
Cash & equivalents	$66.00M	$40.27M	$57.05M	$16.98M
Total assets	$68.49M	$68.92M	$69.40M	$66.65M
Total liabilities	$8.02M	$9.90M	$44.59M	$2.76M
Shareholders' equity	$60.47M	$59.02M	$24.80M	$63.90M
Return on year-end equity	-59.7%	14.5%	-245.2%	-12.2%
Shares outstanding	91.88M	56.41M	48.60M	n/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Context Therapeutics Inc.	Spero Therapeutics, Inc.	Werewolf Therapeutics, Inc.	Grace Therapeutics, Inc.
Latest	n/a	$66.80M Ended 2025-12-31	n/a	$100.00M Ended 2022-03-31
1 year earlier	n/a	$47.98M Ended 2024-12-31	n/a	n/a
2 years earlier	n/a	$103.78M Ended 2023-12-31	n/a	n/a
3 years earlier	n/a	$53.51M Ended 2022-12-31	n/a	n/a
4 years earlier	n/a	$18.26M Ended 2021-12-31	n/a	n/a